📰 Davida Cory News
Davida Cory News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Davida Cory. Real-time updates on events, politics, business and more.
May 11, 2023
Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Rating) will be releasing its earnings data on Friday, May 12th. Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Rating) last released its earnings results on Thursday, March 16th. The biotechnology company reported ($0.57) earnings per share for the quarter. Eiger BioPharmaceuticals had a negative return on equity of 115.96% and a negative […]
May 3, 2023
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Rating) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,710,000 shares, an increase of 9.3% from the March 31st total of 2,480,000 shares. Based on an average daily volume of 626,100 shares, the […]
April 3, 2023
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,240,000 shares, an increase of 12.6% from the February 28th total of 1,990,000 shares. Based on an average daily trading volume, of 756,500 shares, […]
March 25, 2023
Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Rating) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.41 and traded as low as $0.95. Eiger BioPharmaceuticals shares last traded at $1.01, with a volume of 335,495 shares traded. Wall Street Analyst Weigh In A […]
April 2, 2022
StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Rating) in a report released on Thursday. The firm set a “sell” rating on the biotechnology company’s stock. Separately, Zacks Investment Research lowered Eiger BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 16th. Shares of NASDAQ:EIGR […]
March 18, 2022
Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly […]